Purpose: The number of pediatric inflammatory bowel disease (IBD) patients receiving long-term immuno-suppressive therapy (IS) has increased in the past several years. The administration of live attenuated vaccines (LAV) should be avoided in these patients. Our needs assessment survey examined current vaccination practices and related knowledge of primary care physicians regarding vaccination of IBD patients receiving IS therapy. Methods: Online close-ended, 13-item questionnaires were sent to primary care physicians, including residents and attendings from pediatrics and family practice at the local institution. Descriptive statistics are reported and comparisons of responses between pediatric and family medicine providers were made using chi-square. Results: Sixty primary care physicians completed questionnaires. Responses represented residents (30%, N=18) and practicing physicians (70%, N=42), and encompassed both pediatric (43%, N=26) and family medicine (57%, N=34) specialties. Most respondents (53%, N=32) have treated pediatric patients on IS therapy; 39% of responders (N=23) review vaccination history at every visit. Nearly all providers identified non-live attenuated vaccines as safe (94-100% depending on vaccine type), and recommend administration to IS patients. However, survey responses identified challenges in provider knowledge and perception of safety surrounding life attenuated vaccines. Intranasal influenza was considered a safe vaccine by 18% of respondents (N=11), varicella by 16% (N=10) and MMR by 32% (N=19). A greater proportion of family medicine physicians considered varicella and MMR vaccine safe to administer in IS patients than did pediatricians (varicella, 24% versus 8%, p=0.2; MMR, 41% versus 19%, P=0.126). Further, fewer family medicine providers (35%, N=12) than pediatricians (69%, N=18) correctly identifi ed all three live attenuated vaccines as unsafe to administer to IS patients (p=0.019). Conclusion: There is significant misconception among primary care physicians regarding safe vaccination practices for pediatric patients receiving IS therapy. More education is necessary for pediatric and family medicine providers to improve physician knowledge and ensure safe immunization administration for pediatric IBD patients receiving long-term immuno-suppressive therapy.